von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.
Aged
Biomarkers
/ blood
Carcinoma, Hepatocellular
/ blood
Female
Hepatectomy
/ mortality
Humans
Liver Neoplasms
/ blood
Male
Middle Aged
Postoperative Complications
/ mortality
Predictive Value of Tests
Prognosis
Risk Assessment
Risk Factors
Survival Rate
Treatment Outcome
von Willebrand Factor
/ analysis
Carcinoma, hepatocellular
Hepatectomy
Outcome
von Willebrand factor
Journal
Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
received:
08
03
2017
revised:
26
10
2017
accepted:
25
11
2017
pubmed:
15
11
2018
medline:
2
2
2021
entrez:
15
11
2018
Statut:
ppublish
Résumé
von Willebrand factor antigen (vWF-Ag) is a noninvasive predictor of portal hypertension that serves as a negative prognostic marker in various malignancies. Increased portal hypertension is associated with higher postoperative morbidity and decreased survival after hepatectomy. The purpose of this study was to determine the correlation between vWF-Ag, postoperative morbidity and oncological outcome. This analysis includes 55 patients who underwent liver resection for hepatocellular carcinoma (HCC) between 2008 and 2015 with available preoperative vWF-Ag levels. The primary endpoints were postoperative complications and long-term outcome, including overall and disease-free survival. The median plasma level of vWF-Ag was 191% (range, 162.5% to 277%). There was a significant correlation between vWF-Ag levels and tumor size in the resected specimens (p=0.010, r=0.350). Patients who developed any grade of postoperative complication had significantly higher preoperative vWF-Ag levels (216% [range, 178% to 283.25%] vs 176% [range, 148% to 246%], p=0.041). Median overall survival was 39.8 months in patients with high vWF-Ag levels (≥191%) compared with 73.4 months in patients with low levels (<191%, p=0.007). Of note, there was a remarkable disparity in the number of patients who died of HCC with low versus high vWF-Ag levels (14.8% vs 28.6%, p=0.011). vWF-Ag may serve as a prognostic marker for the outcome of patients undergoing liver resection for HCC that is closely connected to tumor size, postoperative complication rate and long-term outcome.
Sections du résumé
Background/Aims
von Willebrand factor antigen (vWF-Ag) is a noninvasive predictor of portal hypertension that serves as a negative prognostic marker in various malignancies. Increased portal hypertension is associated with higher postoperative morbidity and decreased survival after hepatectomy. The purpose of this study was to determine the correlation between vWF-Ag, postoperative morbidity and oncological outcome.
Methods
This analysis includes 55 patients who underwent liver resection for hepatocellular carcinoma (HCC) between 2008 and 2015 with available preoperative vWF-Ag levels. The primary endpoints were postoperative complications and long-term outcome, including overall and disease-free survival.
Results
The median plasma level of vWF-Ag was 191% (range, 162.5% to 277%). There was a significant correlation between vWF-Ag levels and tumor size in the resected specimens (p=0.010, r=0.350). Patients who developed any grade of postoperative complication had significantly higher preoperative vWF-Ag levels (216% [range, 178% to 283.25%] vs 176% [range, 148% to 246%], p=0.041). Median overall survival was 39.8 months in patients with high vWF-Ag levels (≥191%) compared with 73.4 months in patients with low levels (<191%, p=0.007). Of note, there was a remarkable disparity in the number of patients who died of HCC with low versus high vWF-Ag levels (14.8% vs 28.6%, p=0.011).
Conclusions
vWF-Ag may serve as a prognostic marker for the outcome of patients undergoing liver resection for HCC that is closely connected to tumor size, postoperative complication rate and long-term outcome.
Identifiants
pubmed: 30428508
pii: gnl17115
doi: 10.5009/gnl17115
pmc: PMC7096232
doi:
Substances chimiques
Biomarkers
0
von Willebrand Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-224Références
Hepatology. 1999 Dec;30(6):1434-40
pubmed: 10573522
Gynecol Oncol. 1993 Jun;49(3):354-8
pubmed: 8314538
Clin Gastroenterol Hepatol. 2011 Jul;9(7):602-8.e1
pubmed: 21397726
J Hepatobiliary Pancreat Surg. 2005;12(5):351-5
pubmed: 16258801
Wien Klin Wochenschr. 2013 Apr;125(7-8):200-19
pubmed: 23579878
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Gut. 2011 Aug;60(8):1133-8
pubmed: 21427197
J Pediatr Hematol Oncol. 2014 Oct;36(7):518-23
pubmed: 25105915
J Natl Cancer Inst. 2008 May 21;100(10):698-711
pubmed: 18477802
Hepatology. 2012 Oct;56(4):1439-47
pubmed: 22532296
Cancer Med. 2016 Aug;5(8):1783-90
pubmed: 27236861
Med Welt. 1982 Jun 25;33(25):909-10
pubmed: 7109938
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Br J Surg. 2011 Sep;98(9):1292-300
pubmed: 21656513
N Engl J Med. 2007 Apr 12;356(15):1545-59
pubmed: 17429086
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
Aliment Pharmacol Ther. 2005 Jan 1;21(1):49-55
pubmed: 15644045
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Am J Gastroenterol. 2007 Nov;102(11):2495-503
pubmed: 17894846
J Am Coll Surg. 2017 Mar;224(3):362-372
pubmed: 27923615
BMC Cancer. 2015 Feb 21;15:80
pubmed: 25886574
Thromb Res. 1996 Sep 1;83(5):399-402
pubmed: 8873348
Oncotarget. 2016 Oct 18;7(42):68527-68545
pubmed: 27602496
Br J Surg. 2012 Sep;99(9):1284-9
pubmed: 22864890
Am J Surg Pathol. 1995 Dec;19(12):1409-17
pubmed: 7503362
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Hepatology. 2015 Feb;61(2):526-36
pubmed: 25212123
Ann Surg Oncol. 2011 Jun;18(6):1644-50
pubmed: 21207168
J Clin Oncol. 2009 Mar 20;27(9):1485-91
pubmed: 19224838
Thromb Res. 2013 Apr;131(4):290-2
pubmed: 23394808
J Phys Chem B. 2013 Sep 26;117(38):11169-75
pubmed: 23506247
Am J Transl Res. 2011;3(5):445-53
pubmed: 22046486
Blood. 2015 May 14;125(20):3153-63
pubmed: 25977583
World J Gastroenterol. 2005 Apr 14;11(14):2166-70
pubmed: 15810086
J Hepatol. 2014 Sep;61(3):544-9
pubmed: 24798623